InvestSMART

Avecho Biotechnology Limited (ASX:AVE)

ALERT: Price-sensitive ASX Announcement for AVE
Current share price for AVE : $0.021 0.012 (133.33%)+
Announcement
Release
27 Feb 2026 4:04PM
Price at Release
$0.009
Full Release
download
Summary
Avecho Biotechnology Limited's Annual Report for the year ended 31 December 2025 outlines the company's financial performance, governance, and strategic initiatives. The report highlights a consolidated loss before income tax of AUD 4.42 million, with no income tax expense recorded for the year. Key management personnel, including the CEO Paul Gavin and COO Roksan Libinaki, were compensated through a mix of salaries and share-based payments. No dividends were declared, and the company has substantial deferred tax assets that remain unrecognized due to uncertainty over future recovery. The company maintains a focus on R&D, with a patent portfolio and employee equity incentive plan in place to encourage long-term growth and shareholder value enhancement. Liquidity and credit risks are managed prudently, with sufficient cash balances and limited exposure to credit defaults.
Key Points
  • Consolidated loss before income tax of AUD 4.42 million.
  • No income tax expense due to unrecognized deferred tax assets.
  • Compensation for key management includes share-based payments.
  • Focus on R&D and maintaining a patent portfolio.
  • Liquidity and credit risks are managed with sufficient cash balances.
  • No dividends were declared for the year.
  • Deferred tax assets remain unrecognized.
  • Equity incentive plan for employees to promote growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.